Most Clicked StoriesMore >


Roche, Mylan to market Herceptin biosimilar globally

DIA Global SmartBrief | Mar 16, 2017

Roche Holding and Mylan have entered into a licensing deal allowing Roche's biosimilar version of Herceptin, or trastuzumab, to be marketed worldwide except in Brazil, Japan and Mexico. The biosimilar drug, which is under FDA review, has been introduced in 14 emerging markets. PMLive.com (U.K.) (03/14)


India proposes digital drug-tracking to ensure quality

DIA Global SmartBrief | Mar 21, 2017

Spinraza to cost $125,000 per injection

DIA Global SmartBrief | Mar 16, 2017

EU, African regulators discuss collaboration on medicine availability

DIA Global SmartBrief | Mar 16, 2017

Sanofi's atopic dermatitis drug accepted for UK's early-access program

DIA Global SmartBrief | Mar 16, 2017

FDA approves Kisqali for metastatic breast cancer

DIA Global SmartBrief | Mar 16, 2017

Teva anticipates key FDA approvals

DIA Global SmartBrief | Mar 16, 2017

Circassia acquires rights to AstraZeneca's COPD drugs

DIA Global SmartBrief | Mar 21, 2017

London clinic uses crowdfunding to improve patient access to cancer drug combo

DIA Global SmartBrief | Mar 16, 2017

DIA CMC Workshop, April 24-26, Rockville, Md.

DIA Global SmartBrief | Mar 21, 2017


Find DIA Global SmartBrief Issues by Date:



DIA News More >


Upcoming Events:

DIA Global SmartBrief | Mar 23, 2017

DIA CMC Workshop, April 24-26, Rockville, Md.

DIA Global SmartBrief | Mar 23, 2017

Upcoming DIA learning opportunities

DIA Global SmartBrief | Mar 09, 2017

Medical Affairs and Scientific Communications Forum, March 13-15, Tucson, Ariz.

DIA Global SmartBrief | Mar 09, 2017




Sign up for DIA Global SmartBrief



Designed specifically for the global drug development professional, the DIA Global SmartBrief is a FREE, twice weekly e-mail newsletter. By providing the latest need-to-know industry news and information, the DIA Global SmartBrief saves you time and keeps you smart. Learn more